Literature DB >> 32283957

HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies.

Guo-Chao Zhong1, Su-Qun Huang2, Yang Peng3, Lun Wan4, You-Qi-Le Wu5, Tian-Yang Hu6, Jie-Jun Hu1, Fa-Bao Hao7.   

Abstract

OBJECTIVE: The association between high-density lipoprotein cholesterol (HDL-C) levels and mortality remains controversial. We aimed to investigate the potential dose-response associations between HDL-C levels and mortality from all causes, cardiovascular disease and cancer in the general population.
METHODS: PubMed and Embase were searched through April 2019. Prospective cohort studies reporting risk estimates of HDL-C levels and mortality were included. Linear and non-linear dose-response analyses were conducted. A random-effects model was employed to calculate pooled hazard ratio.
RESULTS: Thirty-seven studies, involving 3,524,505 participants and more than 612,027 deaths, were included. HDL-C level was found to be associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response pattern, with the lowest risk observed at HDL-C levels of 54-58 mg/dL, 68-71 mg/dL and 64-68 mg/dL, respectively. Compared with HDL-C level of 56 mg/dL, the pooled hazard ratios for all-cause mortality were 1.03 (95% confidence interval (CI) 1.01, 1.05) and 1.10 (95% CI 1.09, 1.12) for each 10-mg/dL increase and decrease in HDL-C levels, respectively; furthermore, compared with the reference category, the pooled hazard ratios for all-cause mortality were 1.21 (95% CI 1.09, 1.36) and 1.36 (95% CI 1.21, 1.53) for the highest and the lowest categories of HDL-C levels, respectively. Similar results were obtained for cardiovascular and cancer mortality.
CONCLUSIONS: In the general population, HDL-C level is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response manner; both extremely high and low HDL-C levels are associated with an increased risk of mortality.

Entities:  

Keywords:  HDL-C; cancer; cardiovascular disease; dose–response; mortality

Year:  2020        PMID: 32283957     DOI: 10.1177/2047487320914756

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  17 in total

1.  U-Shaped Association of High-Density Lipoprotein Cholesterol with All-Cause and Cardiovascular Mortality in Hypertensive Population.

Authors:  Chao-Lei Chen; Xiao-Cong Liu; Lin Liu; Kenneth Lo; Yu-Ling Yu; Jia-Yi Huang; Yu-Qing Huang; Ji-Yan Chen
Journal:  Risk Manag Healthc Policy       Date:  2020-10-08

2.  Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies.

Authors:  Trine L Wilkens; Kaare Tranæs; Jane N Eriksen; Lars O Dragsted
Journal:  Nutr Rev       Date:  2022-04-08       Impact factor: 6.846

3.  Microarray analysis of long non-coding RNA expression profiles in low high-density lipoprotein cholesterol disease.

Authors:  Xinping Wang; Shuxia Guo; Yunhua Hu; Heng Guo; Xianghui Zhang; Yizhong Yan; Jiaolong Ma; Yu Li; Haixia Wang; Jia He; Rulin Ma
Journal:  Lipids Health Dis       Date:  2020-07-28       Impact factor: 3.876

Review 4.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

5.  Higher Serum Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio Is Associated with Increased Mortality among Incident Peritoneal Dialysis Patients.

Authors:  Hee-Won Noh; Yena Jeon; Ji-Hye Kim; Ga-Young Lee; Soo-Jee Jeon; Kyu-Yeun Kim; Jeong-Hoon Lim; Hee-Yeon Jung; Ji-Young Choi; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim; Jang-Hee Cho
Journal:  Nutrients       Date:  2021-12-29       Impact factor: 5.717

6.  Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.

Authors:  Fan Luo; Kang-Mei Zeng; Jia-Xin Cao; Ting Zhou; Su-Xia Lin; Wen-Juan Ma; Yun-Peng Yang; Zhong-Han Zhang; Fei-Teng Lu; Yan Huang; Hong-Yun Zhao; Li Zhang
Journal:  Lipids Health Dis       Date:  2021-09-20       Impact factor: 3.876

7.  The Associations of Lipid Profiles With Cardiovascular Diseases and Death in a 10-Year Prospective Cohort Study.

Authors:  Jiayi Dong; Song Yang; Qian Zhuang; Junxiang Sun; Pengfei Wei; Xianghai Zhao; Yanchun Chen; Xiaotian Chen; Mengxia Li; Lai Wei; Changying Chen; Yao Fan; Chong Shen
Journal:  Front Cardiovasc Med       Date:  2021-11-25

Review 8.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

Review 9.  HDL Is Not Dead Yet.

Authors:  Shuhui Wang Lorkowski; Jonathan D Smith
Journal:  Biomedicines       Date:  2022-01-07

10.  A Non-Linear Association of High-Density Lipoprotein Cholesterol with All-Cause and Cause-Specific Mortality in Diabetic Patients.

Authors:  Yu-Qin Yan; Jun Chen; Yu-Qing Huang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-22       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.